Signify Premium Insight: Riding out the Storm: Amwell and Teladoc Financials Q4/FY2022

Published: March 2, 2023

In the face of sustained macro-economic challenges, Amwell and Teladoc continue to wage battle on several fronts. As in previous quarters, Teladoc is riding out the post-Covid storm better than its rival on several counts. But, amid the pervading global gloom, the telehealth industry is in decent overall shape; and there are some genuine bright spots in both companies’ Q4 and full-year (FY) 2022 financial results. This offers grounds for guarded optimism in 2023 and beyond. 

Amwell at a Loss  

By far Amwell’s most pressing challenge is how to stem losses which have been a black mark on the company’s bottom line since the end of the Covid telehealth boom. In 2022, soaring inflation intensified the problem, pushing operating expenses ever higher.  

Already have an account? Sign in here